CXCR1 and melanoma: Moreover, the disruption of CXCR1/2 through SX-682 has shown efficacy in mice (21, 258), and its combinatorial treatment with PD-L1-targeted antibody, pembrolizumab, is also being studied in a phase 1 trial in melanoma (NCT03161421).